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Abstract Thimerosal added to some pediatric vaccines is
suspected in pathogenesis of several neurodevelopmental
disorders. Our previous study showed that thimerosal
administered to suckling rats causes persistent, endogenous
opioid-mediated hypoalgesia. Here we examined, using
immunohistochemical staining technique, the density of
l-opioid receptors (MORs) in the brains of rats, which in
the second postnatal week received four i.m. injections of
thimerosal at doses 12, 240, 1,440 or 3,000 lg Hg/kg. The
periaqueductal gray, caudate putamen and hippocampus
were examined. Thimerosal administration caused dose-
dependent statistically significant increase in MOR densi-
ties in the periaqueductal gray and caudate putamen, but
decrease in the dentate gyrus, where it was accompanied by
the presence of degenerating neurons and loss of synaptic
vesicle marker (synaptophysin). These data document that
exposure to thimerosal during early postnatal life produces
lasting alterations in the densities of brain opioid receptors
along with other neuropathological changes, which may
disturb brain development.
Keywords Thimerosal  Mu opioid receptors  Rat 
Brain  Development
Introduction
Thimerosal (THIM), an organomercury compound, which
contains approximately 49% mercury (Hg) by weight, has
been used for decades as a preservative in pediatric vaccines
without adequate testing for its safety in developing organ-
isms. THIM is metabolized in the body first into ethyl-
mercury and subsequently into other organic and inorganic
mercury forms [1]. Centuries of human experience and a
large body of scientific data document that all forms of Hg
are highly toxic. Considerable amounts of Hg have been
found in the blood of human infants after the injection of
THIM-containing vaccines [2, 3] and studies conducted with
infant monkeys showed that Hg from THIM-vaccine injec-
tions accumulates in the brain at concentrations many times
higher than those in the blood, and that it stays there for
months or years [4]. Post vaccination levels of Hg in infant
brains may reach medium nanomolar concentrations, which
are neurotoxic and kill neurons in vitro [5]. THIM doses
equivalent to those used in vaccines have been shown to
harm the brains of developing mice [6].
Early life exposure to mercurials, including THIM, is
suspected to be a pathogenic factor in several neurode-
velopmental disorders [7–10]. We have previously shown
that THIM administration to suckling rats in a mode similar
to infant immunization and at doses analogous to those
used in pediatric vaccines, or higher, persistently augments
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the activity of endogenous opioid system in adult animals,
manifested by hypoalgesia (blocked by naloxone) and
enhanced sensitivity to morphine [11]. The precise neuro-
chemical mechanism of this effect is unknown at present,
but could be complex. It may be due to increased pro-
duction of endogenous or food-derived opioids, their
decreased degradation, an amplified expression of l opioid
receptors (MORs), or to other factors. Possible involve-
ment of opioid receptors in the hypoalgesic effect of THIM
is suggested by the study of Zanoli et al. [12], which
showed that administration of methylmercury to pregnant
rats augmented the density of MORs in the brains of their
offspring. Methylmercury is pharmacodynamically very
similar to ethylmercury, although it somewhat differs from
it in pharmacokinetics [1, 4, 13].
The present study is a follow-up of our earlier research.
Here we examined, using immunohistochemical technique,
the density of MORs in the brains of young adult rats,
which in early postnatal life were treated with different
doses of THIM. We concentrated on analysis of the brain
regions rich in opioid receptors, such as the periaqueductal
gray (PAG), the caudate putamen (CPU) and the hippo-
campus [14, 15].
Experimental Procedures
Animals and Drug Administration
Pregnant Wistar rats were supplied by a breeder (Medical
Research Centre, Polish Academy of Sciences, Warsaw,
Poland). The animals were kept in a room under standard
environmental conditions until breeding (22 ± 1C, a rel-
ative humidity of 60%, a 12 h–12 h light–dark cycle with
lights on at 07:00 h). Standard laboratory chow (Labofeed
H, WPIK, Kcynia, Poland) and tap water were available
ad libitum. All experiments were conducted according to
the ethical standards laid down in respective Polish and
European (directive No. 86/609/EEC) regulations. All
procedures were reviewed and approved by the local ethics
committee on animal studies.
THIM from Sigma–Aldrich, Poland, was used in the
experiments. The Hg content in THIM substance was ana-
lyzed by the accredited Chemical Laboratory of Multi-
Elemental Analyses at Wroclaw University of Technology
by the method of atomic absorption spectroscopy. Accord-
ing to their analysis, the Hg content in THIM was 48%.
THIM dissolved in saline was injected into newborn rats on
the postnatal days 7, 9, 11 and 15 in four equal doses
(12–3,000 lg Hg/kg) in a volume of 50 ll, i.m. into glutei
maximi, as described before [11], according to the method
of Hornig et al. [6]. The lowest dose used (12 lg Hg/kg) is in
the order of THIM doses still present in infant vaccines in
many countries [11]. Analogous doses were used in studies
in developing mice and monkeys by other investigators [4,
6]. Control rats received saline injections following the
same scheme. Rats from one litter received the same treat-
ment. There were 4–7 litters per dose-treatment. Each ani-
mal was weighed before THIM injection, and the amount of
the drug given was adjusted to its weight. Weights of rats at
the time of drug injections on postnatal days 7, 9, 11 and 15
were, respectively: 13.5 ± 1.7, 16.5 ± 1.7, 21.3 ± 2.2,
28 ? 2.1 g (average ± SEM; N = 124). Pups were weaned
on the 28th postnatal day and on that day were separated into
male and female cages.
Brain Acquisition
On the 20th postnatal week, the animals were euthanized by
pentobarbital overdosing (Biowet Puławy, Poland), and then
decapitated. The rats treated with two higher doses of THIM
(1,440 and 3,000 lg Hg/kg) were from the original litters,
which were used for different behavioral and pathological
tests [11], but were experimentally naı¨ve. A separate group
of experimentally naı¨ve rats, treated with two lower doses of
THIM, 12 and 240 lg Hg/kg (4 litters per each drug-treat-
ment) was sacrificed on the 8th postnatal week according to
the same procedure. Each experimental group was com-
posed of 5 animals, with 2 at the most coming from the same
litter. Only males were used in the present study.
The brains were removed within 30 s after decapitation
and placed into a buffered formaldehyde solution for 24 h.
After that they were passed through ethanol solutions of
increasing concentrations (60–100%) and xylene, finishing
with paraffin. The paraffin blocks were stored in a refrig-
erator at 3C until the slicing. The brains were sliced using
a microtome, and the sections were gently placed on basic
microscope glasses covered previously with L-silane. The
section thickness was 4 microns. The sliced tissue was
placed in an incubator set at 56C for 3 h.
H.E. Staining
To evaluate gross tissue pathology, the corresponding
specimens showing hippocampus (Bregma -3.84) [16] were
sequentially executed through following stages: xylene,
ethanol, water, then with hematoxylin (5 min), rinsed with
water (10 min) treated with eosin (1 min), rinsed with
water (2 min), then washed with ethanol and xylene, finally
immersed with Histofluid using cover glasses.
Immunohistochemistry and Receptor Density Counting
The specimens were stained using Rabbit Anti-Mu Opioid
Receptor Monoclonal Antibody Clone EP1470Y (1:100)
(from Abcam, USA) and R.T.U. Vectastain Kit (from
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Vector Laboratories, USA), and then treated with: diam-
inobenzidine and hydrogen peroxide solution (1 ml
DAB ? 1 ml TRIS–EDTA solution ? 1.6 ll 30% hydro-
gen peroxide; 3 min), ethanol, xylene, finally immersed in
Histofluid (Marienfeld) using cover glasses. The micro-
photographs of the brain sections were made with the
Olympus BX41 microscope and Olympus DP25 digital
camera. The images were saved in TIFF format. For each
experiment microphotographs were made with the same
light level for all sections.
To evaluate MOR density, the following sections were
used for analysis: (1) sections showing the periaqueductal
gray (PAG) (Bregma -6.36) included regions: the dorso-
medial periaqueductal gray (DMPAG) and the lateral peri-
aqueductal gray (LPAG); (2) sections showing the caudate
putamen (Bregma -1.20) were analyzed in the North-East
quadrant; (3) sections showing the hippocampus (Bregma
-3.60) were used to analyze the dentate gyrus. The position
of the regions was determined according to the rat brain atlas
[16]. For analysis of receptor density, microphotographs of
each region were taken with a magnification of 4009 (area
of 35452.23 lm2). The MOR density was counted as an area
fraction in the analyzed region, with ImageJ 1,41o software
and used for statistical analysis. The area fraction was
automatically counted with a ‘‘threshold’’ function of the
ImageJ program, which marks all the pixels of chosen gray
value and counts all the groups of marked pixels (stained
receptors) within the selected area [17].
Synaptophysin Reaction
Synaptophysin immunoreactivity was uses as a marker of
synaptic density. The specimens were stained using Syn-
aptophysin Lyophilized Mouse Monoclonal Antibody
(Novocastra). They were executed through following
stages: deparaffination (xylene, ethanol, water), antigens
uncovering by heating (microwave, 15 min, 1,200 W) in
citrate buffer (0.01 M, pH 6.0), methanol and 3% hydrogen
peroxide solution (20 min), TRIS-saline (15 min, pH 7.6),
serum swine (60 min) (Daco, Poland), primary antibody
Synaptophysin Lyophilized Mouse Monoclonal Antibody
(1:100, over night) (Millipore), TRIS-saline (15 min,
pH 7.6), secondary antibody JgG Mouse (1:200, 45 min)
(Sigma, Poland), TRIS-saline (15 min, pH 7.6), streptavi-
dine (1:500, 60 min) (Sigma), TRIS-saline (15 min, pH
7.6), diaminobenzidine and hydrogen peroxide solution
(3 min), ethanol, xylene, and finally immersed with
Histofluid using cover glasses.
Synaptic Density Counting
To assess the synaptic density, sections showing synapto-
physin reaction in the hippocampus (CA3 field) were
analyzed. Positions of the regions were determined
according to the rat brain atlas (around Bregma -3.84 mm).
Microphotographs of each region were taken from both
cerebral hemispheres with magnification of 200 (area
141808.92 lm2). The synaptic density (stained synapses)
was counted in a manner similar to counting MORs with
ImageJ 1,41o software. Two corresponding areas from
opposite hemispheres per animal per structure were ana-
lyzed. The synaptic density from each side and structure
was averaged for each animal and used for statistical
analysis.
Statistical Analysis
The STATISTICA software package for Windows (Stat-
Soft, Tulsa, OK, USA) was used to analyze all data. An
analysis of variance (ANOVA) was used to compare
experimental groups. An LSD test was employed for
individual post-hoc comparisons. Probability (P) levels less
than 0.05 was considered significant.
Results
Results presented in Fig. 1 and Tables 1, 2 and 3 show that
early postnatal THIM administration changes MOR density
in several brain regions of adult rats (N = 5 per experi-
mental group). Figure 1 illustrates examples of photographs
of the analyzed brain regions. The brains of control animals
and those that received four injections of lower doses of
THIM (12 and 240 lg Hg/kg), were examined on the 8th
postnatal week for MOR density in the PAG region. The
THIM administration increased MOR density in the PAG
in a dose-dependent manner (Table 1). One way ANOVA
(Hg dose) revealed statistically significant effect of dose
[F(2,6) = 8.087; P = 0.019] in the dorsomedial periaqu-
eductal gray (DMPAG). The post-hoc analysis confirmed a
significant effect at dose 240 lg Hg/kg (P = 0.007). In the
lateral periaqueductal gray (LPAG) a similar trend was
observed, even though one way ANOVA revealed a non-
significant effect of Hg dose [F(2,8) = 3.514; P = 0.08].
The brains of the control rats and those treated with
higher doses of THIM (1,440 and 3,000 lg Hg/kg) were
assessed for MOR density on the 20th postnatal week
(N = 5 per experimental group). The PAG region, caudate
putamen (CPU) and dentate gyrus (DG) were examined.
Treatment with both doses of THIM statistically signifi-
cantly increased MOR density in the DMPAG and LPAG
regions (Table 2). For the DMPAG, one way ANOVA
revealed statistically significant effect of dose [F(2,12) =
13.757; P \ 0.001]. The post-hoc analysis confirmed a
significant effects at the doses 1,440 lg Hg/kg (P \ 0.001)
and 3,000 lg Hg/kg (P = 0.009). For the LPAG, one way
1842 Neurochem Res (2010) 35:1840–1847
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Fig. 1 Changes in MOR
density in different brain
structures of neonatally THIM-
treated rats. Images are
representative photographs of
MOR reaction, visualized as
brown/dark rings around cells
(pointed with arrows). THIM
administration led to increase of
MOR density in the PAG
(a–d) and the CPU
(g–h) (increase pointed with
black arrows), but to decrease
of MOR density in the DG
(e–f) (decrease pointed with
white arrows). a DMPAG,
control, 8-week, 9400;
b DMPAG, 240 lg Hg/kg,
8-week, 9400; c DMPAG,
control, 20-week, 9400;
d DMPAG, 3,000 lg Hg/kg,
20-week, 9400; e DG, control,
20-week, 9100; f DG, 3,000 lg
Hg/kg, 20-week, 9100; g CPU,
Control, 20-week, 9400;
h CPU, 3,000 lg Hg/kg,
20-week, 9400. For
interpretation of the references
to color in this figure legend, the
reader is referred to the online
version of this article
Table 1 Effect of postnatal THIM treatment on MOR density in the PAG area in 8-week old rats: lower doses of THIM
Hg dose (lg/kg) DMPAG LPAG
AV-AF ±SEM P % CTRL AV-AF ±SEM P % CTRL
0 4.39 1.79 100 1.76 0.35 100
12 14.44 1.94 n.s. 328 4.19 1.16 n.s. 238
240 21.36 4.47 0.007 485 8.29 2.73 n.s. 471
AV-AF Average stained area fraction (% of the area), % CTRL percent of control value, P significancy. Neonatal rats’ exposure to THIM doses
12 and 240 lg/kg causes increases in MOR density in DMPAG and LPAG areas. Statistical analysis is described in the ‘‘Results’’ section
Neurochem Res (2010) 35:1840–1847 1843
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ANOVA revealed statistically significant effect of dose
[F(2,12) = 14.235; P \0.001] and the post-hoc analysis
confirmed such effect at both doses, 1,440 and 3,000 lg Hg/kg
(P \ 0.001). In the DMPAG, the increasing trend was
observed up to dose 1,440 lg Hg/kg, where MOR density
reached 717% of control, and in the LPAG—up to a dose of
3,000 lg Hg/kg, where it reached 1,546% of control value.
These data clearly show that neonatal THIM treatment
produces dose-dependent increases in MOR density in the
PAG area. This effect is long lasting, as it persists until at
least the postnatal week 20th. Very likely it is permanent.
At the dose 3,000 lg Hg/kg, THIM also augmented
MOR density in the CPU. In contrast, the administration of
THIM at both higher doses decreased MOR density in the
DG (Table 3). This reduction was dose-dependent, reaching
67 and 18% of the control value at doses 1,440 and 3,000 lg
Hg/kg, respectively. For the CPU area, one way ANOVA
revealed statistically significant effect of dose [F(2,6) =
6.948; P \ 0.02] and the post-hoc analysis confirmed such
effect at dose 3,000 lg Hg/kg (P = 0.02). For the DG area,
one way ANOVA revealed statistically significant effect of
dose [F(2,6) = 6.948; P \ 0.02] and the post-hoc analysis
confirmed such effect at doses 1,440 lg Hg/kg (P \ 0.02)
and 3,000 lg Hg/kg (P = 0.005).
In order to assess if the THIM-induced decline of MOR
density in the DG was due to a potential loss of hippocampal
neurons or synapses, we conducted a neuropathological
examination of this brain region. Figure 2A–C illustrates
examples of neuropathological changes in the dorsal hip-
pocampus (Bregma -3.60) of rats, which at neonatal stage
received four injections of THIM at doses 12 or 240 lg Hg/
kg (N = 5 per group). Characteristic ischemic-like degen-
eration of neurons and dark neurons were observed in the
granular layer of the DG area, CA1 and CA3 fields in THIM-
treated rats. These pathological changes were more exten-
sive in animals treated with higher doses of THIM. Neurons
in the control group looked normal.
To evaluate possible changes in synaptic density, the
hippocampi of experimental animals were examined for
immunoreactivity to synaptophysin—the protein marker for
presynaptic vesicles. Synaptophysin reaction was drastically
diminished in tissues from THIM-injected rats (Fig. 2D–E),
suggesting reduced synaptic content or decreased synapto-
physin concentration in synaptic vesicles. In the hippocam-
pus CA3 fields from animals treated with THIM dose 12 lg
Hg/kg, the synaptophysin reaction was reduced on average
by 47% and in the tissues from rats treated with THIM dose
240 lg Hg/kg, it was reduced by 61% (N = 5 per experi-
mental group). The one way ANOVA revealed a significant
effect of Hg dose [F(2,24) = 12.323; P \ 0.001] and the
post-hoc analysis confirmed such effect for THIM doses 12
and 240 lg Hg/kg (P \ 0.05).
Discussion
The present study extends our earlier finding of persistent
hypoalgesia, apparently mediated by endogenous opioids, in
rats exposed to THIM during the early postnatal period [11].
We now show that neonatal THIM administration also
Table 2 Effect of postnatal THIM treatment on MOR density in the PAG area in 20-week old rats: higher doses of THIM
Hg dose (lg/kg) DMPAG LPAG
AV-AF ±SEM P % CTRL AV-AF ±SEM P % CTRL
0 0.95 0.208 100 0.222 0.060 100
1,440 6.85 1.202 \0.001 717 3.179 0.619 \0.001 1,432
3,000 4.47 0.656 0.009 468 3.432 0.533 \0.001 1,546
AV-AF Average stained area fraction (% of the area), % CTRL percent of control value, P significancy. Neonatal rats’ exposure to THIM doses
1,440 and 3,000 lg/kg causes increases in MOR density in DMPAG and LPAG areas. Statistical analysis is described in the ‘‘Results’’ section
Table 3 Effect of postnatal THIM treatment on MOR density in the caudate putamen (CPU) and the dentate gyrus (DG) areas in 20-week
old rats
Hg dose (lg/kg) CPU DG
AV-AF ±SEM P % CTRL AV-AF ±SEM P % CTRL
0 3.583 0.456 100 1.655 0.612 100
1,440 3.835 0.913 n.s. 107 1.117 0.444 0.02 67
3,000 8.301 2.553 0.02 232 0.307 0.132 0.005 18
AV-AF Average stained area fraction (% of the area), % CTRL percent of control value, P significancy. Neonatal rats’ exposure to THIM doses
1,440 and 3,000 lg/kg causes increase in MOR density in the CPU, but decrease in DG area. Statistical analysis is described in the ‘‘Results’’
section
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changes densities of MORs in several brain regions. A
marked THIM-induced, dose-dependent increase of MOR
density was found in the PAG—the midbrain region asso-
ciated with pain modulation [18–20]. The effect was clearly
noticeable already at the lowest dose of THIM (12 lg Hg/
kg), equivalent to those used in pediatric vaccines, although
at this dose it did not reach statistical significance. However
in behavioral tests, the same dose produced statistically
significant hypoalgesia [11]. At higher doses of THIM,
statistically significant increases of MOR density were
observed in this brain region. Similar effect was noted in the
CPU, though only at the highest dose of THIM. The opposite
trend was seen in the DG, where THIM treatment led to a
substantial reduction in MOR density.
Our finding of augmented MOR density in the PAG and
CPU regions in adult rats, which were exposed to THIM in
early postnatal life, resembles the study results of Zanoli
et al. [12] in the brains of rats exposed to methylmercury in
utero. The neurochemical/cellular mechanism(s) underly-
ing these changes are not known at present; their elucida-
tion requires further studies. Nonetheless, several
possibilities are worth taking into consideration. In vitro,
mercurials inhibit ligand binding to MOR [21] due to the
formation of Hg adducts with the receptor’s—SH groups,
critical for its function [22–24]. It is possible that the
THIM-induced increase in MOR density represents
enduring, compensatory receptor upregulation, which
resembles the effect of chronic treatment with opiate
receptor antagonist [25]. Another potential mechanism may
involve the activity of certain inflammatory cytokines,
which can induce MOR gene expression in neuronal and
immune cells [26], as production of these molecules is
stimulated by THIM [27]. Moreover, since the second
postnatal week, when our animals received THIM injec-
tions, coincides with rapid amplification of MORs in the rat
brain [28, 29], it is possible that THIM interfered with this
process by altering receptor gene expression through direct
or indirect pathways [30, 31]. Other mechanisms of MORs’
amplification cannot be excluded.
In the DG, unlike in the PAG area, neonatal THIM
injections caused reduction in MOR density. It is not clear
at present, why MORs in this brain region respond differ-
ently to mercurial exposure than those in the PAG or CPU.
In other experiments, chronic rat treatment with an opiate
receptor antagonist, led to up regulation of hippocampal
MORs, analogous to that in the PAG and other brain
regions [25], but seizures induced by pilocarpine resulted
in decrease of MOR density in the DG [32]. Distinct
response of MORs in the DG to THIM treatment may be
due to different functional role of these receptors in the
hippocampus than in other brain structures. While in most
brain areas MORs are mostly postsynaptic and exert
neuroinhibitory effects, a substantial proportion of hippo-
campal MORs are presynaptic, located on GABAergic
interneurons, which are inhibited by activity of these
receptors, exerting net excitatory actions [33].
The mechanism of THIM-induced decline of hippo-
campal MORs may be complex. It may be due to disrupted
Fig. 2 Neuropathological changes in the hippocampi of neonatally
THIM-treated rats, 8-week old. Images a–c show dark neurons and
ischemic-like degeneration (marked with black arrows) of the
hippocampal neurons in the dentate gyrus of THIM-treated rats.
a Control group; b THIM dose 12 lg Hg/kg; c THIM dose 240 lg
Hg/kg; magnification 9400. Images d–e show diminished synapto-
physin reaction (loss of synapses or synaptic marker protein) in the
hippocampi of THIM-treated rats (marked with white arrows).
d Control group; e THIM dose 240 lg Hg/kg; magnification 9200
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receptor ontogenesis, which is most active during the first
two postnatal weeks in rats [29], due to functional recep-
tors’ down regulation, or loss of MORs containing neurons
or synapses. The latter possibility is quite probable, as
pathological examination of the hippocampi from THIM-
treated rats revealed ischemic-like degenerating and dark
neurons in the DG, accompanied by a striking reduction of
synaptophysin content. Analogous loss of synaptophysin
accompanied by inflammatory processes was induced in
immature rats by exposure to lead, indicating neurotoxic/
neurodegenerative processes [34]. Because in rats the sec-
ond postnatal week is a period of dynamic developmental
changes in hippocampal synaptogenesis [35], the loss of
synaptophysin in THIM-exposed animals may suggest dis-
ruption of this process, excessive synaptic pruning, or neu-
ronal degeneration. The parallel down regulation or loss of
hippocampal MORs and synaptophysin is consistent with
the finding, that this protein regulates MOR trafficking and
signaling [36]. Pathophysiological consequences of THIM-
induced changes in the hippocampus are likely to be con-
siderable, as opioids modulate many hippocampal functions
including the development of neonatal neurotransmitter sys-
tems, neuronal excitability, learning, neurogenesis, neuro-
nal survival, stress reactions and other functions [33, 37].
Alterations of MOR densities in the brains of THIM-
exposed animals are expected to have significant patho-
physiological effects. Since the PAG is involved in pain
regulation [18–20], an increase of MOR density in this
region is likely to augment the activity of endogenous and
exogenous opioids. Indeed we observed such an effect in
THIM-treated rats in the form of hypoalgesia and amplified
sensitivity to morphine [11]. These preclinical findings can
be extrapolated, with caution, to certain clinical situations,
particularly to a spectrum of neurodevelopmental disor-
ders, where THIM is a suspected iatrogenic factor. It is
possible that in the brains of susceptible infants, e.g. those
with impaired capacity for metal elimination [38, 39]
or with other biologic vulnerabilities, administration of
THIM-containing vaccines may cause similar changes in
MORs, as are seen in rats. This would alter sensitivity of
such children to endogenous opioids. Such changes may
contribute to dysfunctional opioid system in autistic indi-
viduals [40, 41] and may be responsible, at least in part, for
their anecdotally reported impaired nociception and
increased sensitivity to food-derived exomorphins (caso-
morphin and gliadomorphin). MORs upregulation in the
PAG may as well affect other physiological functions such
as heart rate, feeding, sleep and motor activity [19], which
are often disturbed in autistics [42].
Our earlier pharmacokinetic study documented that Hg
from i.m. THIM administration rapidly accumulates in the
rat brain, with peak levels reached 4 days after the injec-
tion, and that it remains there for many weeks and possibly
months [11]. The neurotoxic/pathological changes are
probably initiated during a few days after injections of
THIM, when its brain concentrations are the highest, but are
likely to continue for months or be permanent, as docu-
mented by the results of our neuropathological and behav-
ioral experiments, conducted many weeks after THIM
administration. The persistent alterations of brain opioid
systems ensuing from early life exposure to THIM is just one
element of a plethora of neurodevelopmental pathologies
induced by this mercurial in animals and humans [6–9, 11].
Its harmful effects are likely to be augmented by other vac-
cine adjuvants, such as aluminum, formaldehyde or antibi-
otics, and by various environmental toxins [31, 43, 44].
Particularly aluminum compounds, added to vaccines to
augment their immunogenicity, have been shown to syner-
gistically potentiate THIM’s neurotoxicity [43]. Thus in the
presence of other toxins or substances, which per se may be
rather innocuous, even small doses of THIM in vaccines can
lead to neurological injury in vulnerable children.
In conclusion, this study documents that parenteral
administration of THIM to suckling rats at doses equivalent
to those used in pediatric vaccines or higher produces
lasting alterations of MORs in several brain regions and
damage to neurons. If analogous changes occur in the
brains of some children, they are likely to have profound
neurological, physiological and behavioral consequences,
which may be relevant for certain neurodevelopmental
disorders. These data argue for removal of THIM from all
infant vaccines.
Acknowledgments This publication is a part of ASTER project
funded by the European Commission grant (MEXC-CT 2006-042371)
and by the supplementary funding from the Ministry of Science and
Higher Education of Poland, both to Maria Dorota Majewska.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Qvarnstro¨m J, Lambertsson L, Havarinasab S, Hultman P, Frech
W (2003) Determination of methylmercury, ethylmercury, and
inorganic mercury in mouse tissues, following administration of
thimerosal, by species-specific isotope dilution GC-inductively
coupled plasma-MS. Anal Chem 75:4120–4124
2. Pichichero ME, Gentile A, Giglio N, Umido V, Clarkson T,
Cernichiari E, Zareba G, Gotelli C, Gotelli M, Yan L, Treanor T
(2008) Mercury levels in newborns and infants after receipt of
thimerosal-containing vaccines. Pediatrics 121:208–214
3. Stajich GV, Lopez GP, Harry SW, Sexson WR (2000) Iatrogenic
exposure to mercury after hepatitis B vaccination in preterm
infants. J Pediatr 136:679–681
4. Burbacher WM, Grant KS, Mayfield DB, Gilbert SG, Rice DC
(2005) Prenatal methylmercury exposure affects spatial vision in
adult monkeys. Toxicol Appl Pharmacol 208:21–28
1846 Neurochem Res (2010) 35:1840–1847
123
5. Yel L, Brown LE, Su K, Gollapudi S, Gupta S (2005) Thimerosal
induces neuronal cell apoptosis by causing cytochrome c and
apoptosis-inducing factor release from mitochondria. Int J Mol
Med 16:971–977
6. Hornig M, Chian D, Lipkin WI (2004) Neurotoxic effects of
postnatal thimerosal are mouse strain dependent. Mol Psychiatry
9:833–845
7. Bernard S, Enayati A, Redwood L, Roger H, Binstock T (2001)
Autism: a novel form of mercury poisoning. Med Hypotheses 56:
462–471
8. Geier MR, Geier DA (2003) Neurodevelopmental disorders after
thimerosal-containing vaccines: a brief communication. Exp Biol
Med 228:660–664
9. Mutter J, Naumann J, Schneider R, Walach H, Haley B (2005)
Mercury and autism: accelerating evidence? Neuroendocrinol
Lett 26:439–446
10. Young H, Geier D, Geier M (2008) Thimerosal exposure in
infants and neurodevelopmental disorders: an assessment of
computerized medical records in the vaccine safety datalink.
J Neurol Sci 271:110–118
11. Olczak M, Duszczyk M, Mierzejewski P, Majewska MD (2009)
Neonatal administration of a vaccine preservative, thimerosal,
produces lasting impairment of nociception and apparent acti-
vation of opioid system in rats. Brain Res 1301:143–151
12. Zanoli P, Truzzi C, Veneri C, Brandoli C, Baraldi M (1997)
Prenatal exposure to methylmercury during late gestation affects
cerebral opiatergic system in rat offspring. Environ Res 74:48–53
13. Magos L, Brown AW, Sparrow S, Bailey E, Snowden RT, Skipp
RS (1985) The comparative toxicology of ethyl- and methyl-
mercury. Arch Toxicol 57:260–267
14. Herkenham M, Pert CB (1980) In vitro autoradiography of opiate
receptors in rat brain suggests loci of ‘‘opiatergic’’ pathways.
Proc Natl Acad Sci USA 77:5532–5536
15. Moskowitz AS, Goodman RR (1985) Autoradiographic distri-
bution of mu1 and mu2 opioid binding in the mouse central
nervous system. Brain Res 360:117–129
16. Paxinos G, Watson C (2007) The rat brain in stereotaxic coor-
dinates. Academic Press, Oxford
17. Anderson BD, Nakamura T, Russell SJ, Peng KW (2004) High
CD46 receptor density determines preferential killing of tumor
cells by oncolytic measles virus. Cancer Res 64:4919–4926
18. Basbaum AI, Fields HL (1978) Endogenous pain control mech-
anisms: review and hypothesis. Ann Neurol 4:451–462
19. Mason P (2005) Ventromedial medulla: pain modulation and
beyond. J Comp Neurol 493:2–8
20. Smith DJ, Perrotti JM, Crisp T, Cabral ME, Long JT, Scalzitti JM
(1988) The mu opiate receptor is responsible for descending pain
inhibition originating in the periaqueductal gray region of the rat
brain. Eur J Pharmacol 156:47–54
21. Tejwani GA, Hanissian SH (1990) Modulation of mu, delta and
kappa opioid receptors in rat brain by metal ions and histidine.
Neuropharmacology 29:445–452
22. Deng HB, Guang W, Wang JB (2000) Selected cysteine residues
in transmembrane domains of mu-opioid receptor are critical
for effects of sulfhydryl reagents. J Pharmacol Exp Ther 293:
113–120
23. Tru¨mpler S, Lohmann W, Meermann B, Buscher W, Sperling M,
Karst U (2009) Interaction of thimerosal with proteins—ethyl-
mercury adduct formation of human serum albumin and b-lac-
toglobulin A. Metallomics 1:87–91
24. Ofri D, Simon EJ (1992) Sulfhydryl groups on opioid receptors
revisited, evidence for two sulfhydryl groups at or near the active
site of the mu opioid receptor. Receptor 2:109–119
25. Tempel A, Gardner EL, Zukin RS (1984) Visualization of opiate
receptor upregulation by light microscopy autoradiography. Proc
Natl Acad Sci USA 81:3893–3897
26. Bo¨rner C, Kraus J, Schro¨der H, Ammer H, Ho¨llt V (2004)
Transcriptional regulation of the human mu-opioid receptor gene
by interleukin-6. Mol Pharmacol 66:1719–1726
27. Havarinasab S, Ha¨ggqvist B, Bjo¨rn E, Pollard JM, Hultman P
(2005) Immunosuppressive and autoimmune effects of thimerosal
in mice. Toxicol Appl Pharmacol 204:109–121
28. Auguy-Valette A, Cros J, Gouarderes C, Gout R, Pontonnier G
(1978) Morphine analgesia and cerebral opiate receptors: a
developmental study. Br J Pharmacol 63:303–308
29. Unnerstall JR, Molliver ME, Kuhar MJ, Palacios JM (1983)
Ontogeny of opiate binding sites in the hippocampus, olfactory
bulb and other regions of the rat forebrain by autoradiographic
methods. Brain Res 283:157–169
30. Glover CN, Zheng D, Jayashankar S, Sales GD, Hogstrand C,
Lundebye AK (2009) Methylmercury speciation influences brain
gene expression and behavior in gestationally-exposed mice
pups. Toxicol Sci 110:389–400
31. Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS,
Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky
VA, Deth RC (2004) Activation of methionine synthase by
insulin-like growth factor-1 and dopamine: a target for neuro-
developmental toxins and thimerosal. Mol Psychiatry 4:358–370
32. Bausch SB, Chavkin C (1997) Changes in hippocampal circuitry
after pilocarpine-induced seizures as revealed by opioid receptor
distribution and activation. J Neurosci 17:477–492
33. Drake CT, Chavkin C, Milner TA (2007) Opioid systems in the
dentate gyrus. Prog Brain Res 163:245–263
34. Struzynska L, Dabrowska-Bouta B, Koza K, Sulkowski G (2007)
Inflammation-like glial response in lead-exposed immature rat
brain. Toxicol Sci 95:156–162
35. Morys´ J, Berdel B, Kowian´ski P, Dziewiatkowski J (1998) The
pattern of synaptophysin changes during the maturation of the
amygdaloid body and hippocampal hilus in the rat. Folia Neu-
ropathol 36:15–23
36. Liang YJ, Wu DF, Yang LQ, Ho¨llt V, Koch T (2007) Interaction
of the mu-opioid receptor with synaptophysin influences receptor
trafficking and signaling. Mol Pharmacol 71:123–131
37. Tegeder I, Geisslinger G (2004) Opioids as modulators of cell
death and survival—unraveling mechanisms and revealing new
indications. Pharmacol Rev 56:351–369
38. Holmes AS, Blaxill MF, Haley BE (2003) Reduced levels of mercury
in first baby haircuts of autistic children. Int J Toxicol 22:277–285
39. Majewska MD, Urbanowicz E, Rok-Bujko P, Namyslowska I,
Mierzejewski P (2010) Age-dependent lower or higher levels of
hair mercury in autistic children than in healthy controls. Acta
Neurobiol Exp (Wars) 70:196–208
40. Sandman CA (1988) Beta-endorphin disregulation in autistic and
self-injurious behavior: a neurodevelopmental hypothesis. Syn-
apse 2:193–199
41. Sandyk R, Gillman M (1986) Infantile autism: a dysfunction of
the opioids? Med. Hypotheses 19:41–45
42. Ming X, Julu PO, Brimacombe M, Connor S, Daniels ML (2005)
Reduced cardiac parasympathetic activity in children with aut-
ism. Brain Dev 27:509–516
43. Haley BE (2005) Mercury toxicity: genetic susceptibility and
synergistic effects. Med Veritas 2:535–542
44. Blaylock RL (2009) A possible central mechanism in autism
spectrum disorders, part 3: the role of excitotoxin food additives
and the synergistic effects of other environmental toxins. Altern
Ther Health Med 15:56–60
Neurochem Res (2010) 35:1840–1847 1847
123
